Aurobindo Pharma Ltd.
Price
Daily candles · NSEPrice history isn’t available for this scrip.
What the numbers say
- Low return on equity: 3-year ROE 10.8%.
- Comfortable leverage: debt-to-equity of 0.20.
- Sales compounded at 10.6% over 3 years.
- Weak cash conversion (CFO/OP 0.57).
- Trades above its industry P/E (26.7 vs 25.9).
Generated automatically from reported financials. These are observations, not a recommendation to buy or sell.
- Aurobindo Pharma gets USFDA’s final nod to manufacture, market Perampanel tablets
The product will be manufactured at Unit-IV of APL Healthcare, a wholly-owned subsidiary of the company and will be launched in Q3FY27
- USFDA concludes inspection at Aurobindo Pharma’s arm’s Telangana facility
The inspection concluded with one observation, which is procedural in nature
- Aurobindo Pharma gets USFDA’s nod for Beclomethasone Dipropionate HFA Inhalation Aerosol
The product will be manufactured at Aurobindo Pharma’s Raleigh facility in North Carolina
- USFDA completes inspection at Aurobindo Pharma’s arm’s Andhra Pradesh facility
The inspection was conducted from September 7 to September 11, 2026 and concluded with zero observations
- Aurobindo Pharma’s arm incorporates wholly owned subsidiary
The object of incorporation of this wholly owned subsidiary is to undertake manufacturing and marketing operations in India and foreign countries
- Aurobindo Pharma’s arm launches generic equivalent of Advair Diskus in US market
Advair Diskus in combination therapy is indicated for the treatment of asthma and chronic obstructive pulmonary disease
- USFDA completes inspection at Aurobindo Pharma’s arm’s Andhra Pradesh facility
The inspection concluded with three observations, which are procedural in nature
- Aurobindo Pharma’s arm receives four observations from USFDA
The USFDA conducted a routine inspection at Lannett Company LLC from August 17 to August 21, 2026
Company announcements as filed with the exchanges. Reproduced for information — not a view or a recommendation.
| Profit & Loss · ₹ crore | FY26 | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| Net Sales | 33,653 | 31,724 | 29,002 | 24,855 | 23,455 |
| Other income | 520 | 622 | 557 | 291 | 323 |
| Total Income | 34,174 | 32,346 | 29,559 | 25,146 | 23,778 |
| Expenditure | 26,836 | 25,141 | 23,159 | 21,137 | 19,071 |
| Operating Profit | 7,338 | 7,205 | 6,400 | 4,009 | 4,707 |
| Interest | 384 | 457 | 290 | 140 | 49 |
| Depreciation | 1,778 | 1,649 | 1,522 | 1,245 | 1,127 |
| Profit before tax | 5,112 | 5,066 | 4,380 | 2,613 | 3,373 |
| Tax | 1,609 | 1,583 | 1,211 | 685 | 726 |
| Net Profit | 3,503 | 3,484 | 3,169 | 1,928 | 2,647 |
| EPS (₹) | 60.34 | 59.81 | 54.16 | 32.90 | 45.19 |
| Net margin % | 10.4 | 11.0 | 10.9 | 7.8 | 11.3 |
Consolidated figures, as filed with the exchanges. Newest year first.
| Balance Sheet · ₹ crore | FY26 | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| Equity capital | 58 | 58 | 59 | 59 | 59 |
| Reserves | 37,833 | 32,595 | 29,784 | 26,781 | 24,517 |
| Net worth | 37,891 | 32,653 | 29,843 | 26,840 | 24,576 |
| Total sources | 40,157 | 34,799 | 32,516 | 28,007 | 25,355 |
| Net block | 17,407 | 14,794 | 14,493 | 11,024 | 10,532 |
| Capital work in progress | 5,214 | 4,900 | 3,869 | 5,390 | 3,747 |
| Investments | 2,437 | 1,635 | 1,342 | 1,404 | 1,610 |
| Inventory | 12,053 | 10,544 | 9,808 | 8,511 | 7,554 |
| Debtors | 7,094 | 5,746 | 4,817 | 4,466 | 4,012 |
| Cash & bank | 9,870 | 8,235 | 6,278 | 6,084 | 4,190 |
| Book value (₹) | 652.39 | 562.21 | 509.35 | 458.10 | 419.46 |
Consolidated figures, as filed with the exchanges. Newest year first.
| Cash Flow · ₹ crore | FY26 | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| From operations | 5,526 | 3,925 | 2,435 | 2,387 | 5,016 |
| From investing | -3,459 | -1,876 | -4,256 | -3,978 | -3,212 |
| From financing | -1,269 | 120 | 800 | 1,814 | -2,969 |
| Net change in cash | 799 | 2,169 | -1,021 | 223 | -1,164 |
| Free cash flow | 2,068 | 2,049 | -1,821 | -1,591 | 1,805 |
| Closing cash | 7,191 | 5,564 | 3,385 | 4,392 | 4,163 |
Consolidated figures, as filed with the exchanges. Newest year first.
| Ratios | FY26 | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| ROCE % | 12.8 | 14.4 | 13.8 | 9.4 | 12.7 |
| ROE % | 9.9 | 11.1 | 11.2 | 7.5 | 11.4 |
| PAT margin % | 5.0 | 5.5 | 5.3 | 3.8 | 5.5 |
| EBIT margin % | 7.9 | 8.7 | 7.8 | 5.4 | 7.2 |
| Debt / equity | 0.20 | 0.24 | 0.21 | 0.18 | 0.10 |
| Current ratio | 1.81 | 1.85 | 1.95 | 1.87 | 2.21 |
| Interest cover | 14.31 | 12.08 | 16.12 | 19.60 | 70.34 |
| Sales growth % | 6.1 | 9.4 | 16.7 | 6.0 | -5.3 |
| Dividend per share (₹) | 4.00 | 0.00 | 4.50 | 3.00 | 9.00 |
| Payout % | 6.6 | 0.0 | 8.3 | 9.1 | 19.9 |
Consolidated figures, as filed with the exchanges. Newest year first.
Frequently asked
Aurobindo Pharma Ltd. (AUROPHARMA) last traded at ₹1,610.90 on the NSE, up +2.03% on the session. Prices on this page are indicative and for information only.
Aurobindo Pharma Ltd. has traded between ₹1,080.10 and ₹1,740.00 over the last 52 weeks on the NSE.
Aurobindo Pharma Ltd. has a market capitalisation of about ₹93,561 crore.
Aurobindo Pharma Ltd. trades at a P/E of 26.7, against an industry P/E of 25.9.
Open a trading and Demat account with Labdhi — it is fully digital with paperless KYC — then place a buy order for AUROPHARMA from the Labdhi app or web platform.
Yes. You can invest in equities in a staggered manner through Labdhi. Speak to your Labdhi adviser about a plan suited to your goals and risk profile.
Who is actually trading it
Delivery against churn, the deals big enough to be reported, what the insiders did, and the benchmarks that hold Aurobindo Pharma Ltd..
Loading trading activity…
Exchange filings and end-of-day data, not a live feed. Bulk, block and insider records are published by the exchanges when a threshold is crossed, so they show reportable activity only. For information, not a recommendation to deal, and not a view on any person named above.
Disclosures. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI, membership of BASL (in case of IAs) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.
Prices and data on this page are indicative and for information only. Nothing here is investment advice or a recommendation to buy or sell any security. Investors should consider their own objectives, financial situation and risk profile, and may wish to seek independent advice, before investing.
Figures are as reported by the company; consolidated where available. Errors and omissions excepted.
L. F. C. Securities Pvt. Ltd. · Member BSE, NSE, MCX · SEBI Stock Broker INZ000170736 · CDSL IN-DP-281-2016 · AMFI ARN-78991 · Investment Adviser (Non-Individual) INA000011617 · Compliance Officer: Mr. Santosh Patil · santoshp@labdhi.in · 022-35006933 · Investor Grievances: investorgreve@labdhi.in